These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33258395)

  • 1. Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia.
    West ZE; Castellino SM; Monroe C; Thomas AS; McCracken C; Miller TP
    Leuk Lymphoma; 2021 Apr; 62(4):899-908. PubMed ID: 33258395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia.
    Warrick K; Althouse SK; Rahrig A; Rupenthal J; Batra S
    Leuk Res; 2018 Aug; 71():36-42. PubMed ID: 30005182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperglycemia requiring insulin during acute lymphoblastic leukemia induction chemotherapy is associated with increased adverse outcomes and healthcare costs.
    McCormick MC; Sharp E; Kalpatthi R; Zullo J; Gurtunca N; Zhang J; Krafty R; Raman S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28475. PubMed ID: 32589365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity in pediatric patients with acute lymphoblastic leukemia increases the risk of adverse events during pre-maintenance chemotherapy.
    Meenan CK; Kelly JA; Wang L; Ritchey AK; Maurer SH
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27515. PubMed ID: 30362242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia.
    Karol SE; Sun Y; Tang L; Pui CH; Ferrolino J; Allison KJ; Cross SJ; Evans WE; Crews KR; Jeha S; Wolf J
    Cancer Med; 2020 Sep; 9(18):6550-6555. PubMed ID: 32710497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher incidence of syndrome of inappropriate antidiuretic hormone secretion during induction chemotherapy of acute lymphoblastic leukemia in indian children.
    Seetharam S; Thankamony P; Gopakumar KG; Krishna KMJ
    Indian J Cancer; 2019; 56(4):320-324. PubMed ID: 31607700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C.
    Pelland-Marcotte MC; Kulkarni K; Tran TH; Stammers D; Gupta S; Sung L; Athale UH
    Am J Hematol; 2024 Feb; 99(2):274-283. PubMed ID: 38164978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucormycosis diagnosed during induction chemotherapy in five pediatric patients with acute lymphoblastic leukemia.
    Aftandilian C; Eguiguren L; Mathew R; Messner A
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27834. PubMed ID: 31131954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia.
    Smitherman AB; Faircloth CB; Deal A; Troy M; Gold SH
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28333402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.
    Denton CC; Rawlins YA; Oberley MJ; Bhojwani D; Orgel E
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29218844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL).
    Dare JM; Moppett JP; Shield JP; Hunt LP; Stevens MC
    Pediatr Blood Cancer; 2013 Dec; 60(12):E157-9. PubMed ID: 23868820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico.
    Vázquez-Cornejo E; Morales-Ríos O; Hernández-Pliego G; Cicero-Oneto C; Garduño-Espinosa J
    PLoS One; 2022; 17(3):e0265450. PubMed ID: 35324939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and predictors of weight loss during induction therapy for childhood acute lymphoblastic leukemia.
    Hill R; Hamby T; Johnson D; Boren C; Downs H; Ray A
    Nutrition; 2021 Jan; 81():110937. PubMed ID: 33045486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
    Sulis ML; Blonquist TM; Stevenson KE; Hunt SK; Kay-Green S; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JG; Neuberg DS; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 May; 65(5):e26952. PubMed ID: 29319209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic Leukemia.
    Almanza-Huante E; Espinosa-Bautista K; Rangel-Patiño J; Demichelis-Gómez R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):55-62.e2. PubMed ID: 32893130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High burden of clinically significant adverse events associated with contemporary therapy for pediatric T-cell acute lymphoblastic leukemia/lymphoma.
    Summers RJ; Monroig VM; DeGroote NP; West ZE; Katafias E; Miller TP
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30571. PubMed ID: 37440329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.
    Farkas T; Müller J; Erdelyi DJ; Csoka M; Kovacs GT
    Pathol Oncol Res; 2017 Oct; 23(4):889-897. PubMed ID: 28138921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.
    Roberson JR; Spraker HL; Shelso J; Zhou Y; Inaba H; Metzger ML; Rubnitz JE; Ribeiro RC; Sandlund JT; Jeha S; Pui CH; Howard SC
    Leukemia; 2009 Feb; 23(2):245-50. PubMed ID: 18923438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.